Why Treat-to-Target Is Being Discussed in Lupus Care
Systemic lupus erythematosus is a long-term autoimmune condition shaped by periods of fluctuation, uncertainty, and cumulative health impact. Historically, management often centered on symptom suppression and flare control, frequently involving prolonged corticosteroid exposure.
The treat-to-target concept described in the 2023 EULAR update reframes care around agreed-upon goals for disease activity and medication burden. This approach highlights the importance of monitoring patterns over time rather than responding only to acute symptoms, while recognizing that individual experiences and priorities vary.
How Treatment Targets Are Described in the Literature
EULAR-aligned discussions of treat-to-target commonly reference disease activity states such as remission or low disease activity, using standardized clinical and laboratory measures. These categories are intended as shared reference points for clinicians and patients rather than fixed endpoints.
Medications such as hydroxychloroquine and, in some cases, biologic therapies are discussed in the literature as tools that may support these goals. Importantly, reported associations between disease activity targets and long-term outcomes reflect population-level trends and do not determine individual trajectories.
Corticosteroid Use as a Long-Term Consideration
Long-term corticosteroid exposure is widely recognized as a contributor to cumulative health burden in lupus, with associations to bone, metabolic, and cardiovascular complications. For this reason, contemporary guidelines increasingly emphasize steroid stewardship, balancing short-term disease control with awareness of longer-term effects.
In research and clinical discussion, this has led to earlier consideration of alternative immunomodulatory strategies and closer attention to cumulative exposure rather than immediate symptom relief alone. Responses to medication adjustments vary and are shaped by disease pattern, comorbidities, and personal context.
Cardiometabolic Health in the Context of Lupus
People living with SLE are known to experience higher rates of cardiovascular and metabolic complications compared to the general population. Inflammation, medication exposure, and traditional risk factors all contribute to this pattern.
Within treat-to-target discussions, cardiometabolic health is framed as an ongoing consideration rather than a separate issue. Research literature highlights the value of regular monitoring and early identification of risk factors, while acknowledging that risk models developed for the general population may not fully capture lupus-specific influences.
Multidisciplinary and Person-Centered Perspectives
Treat-to-target frameworks emphasize collaboration and ongoing dialogue. Rather than focusing solely on laboratory values, this approach encourages attention to fatigue, mental health, sleep, and daily functioning, factors that strongly shape lived experience but are not always reflected in disease activity scores.
Multidisciplinary care models described in the literature may involve coordination between rheumatology, primary care, and other specialties as needed. Digital tools and symptom tracking are sometimes explored as ways to support shared understanding over time, though their use remains context-dependent.
Reflecting on Treat-to-Target as a Framework
Treat-to-target does not describe a cure or a uniform outcome. Instead, it offers a structured way of thinking about long-term management in a condition marked by variability and uncertainty.
The 2023 EULAR recommendations situate success not as complete disease absence, but as an evolving balance between disease activity, treatment burden, and overall health, recognizing that priorities and responses change over time.
References
Fanouriakis, A., Kostopoulou, M., Andersen, J., Aringer, M., Arnaud, L., Bae, S. C., Boletis, J., Bruce, I. N., Cervera, R., Doria, A., Dörner, T., Furie, R. A., Gladman, D. D., Houssiau, F. A., Inês, L. S., Jayne, D., Kouloumas, M., Kovács, L., Mok, C. C., Morand, E. F., … Boumpas, D. T. (2024). EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Annals of the rheumatic diseases, 83(1), 15–29. https://doi.org/10.1136/ard-2023-224762
Pocovi-Gerardino, G., Correa-Rodríguez, M., Callejas-Rubio, J. L., Ríos-Fernández, R., Martín-Amada, M., Cruz-Caparros, M. G., Rueda-Medina, B., & Ortego-Centeno, N. (2021). Beneficial effect of Mediterranean diet on disease activity and cardiovascular risk in systemic lupus erythematosus patients: a cross-sectional study. Rheumatology (Oxford, England), 60(1), 160–169. https://doi.org/10.1093/rheumatology/keaa210
Semalulu, T., Tago, A., Zhao, K., & Tselios, K. (2023). Managing Cardiovascular Risk in Systemic Lupus Erythematosus: Considerations for the Clinician. ImmunoTargets and therapy, 12, 175–186. https://doi.org/10.2147/ITT.S377076
Tsoi, A., Gomez, A., Boström, C., Pezzella, D., Chow, J. W., Girard-Guyonvarc'h, C., Stamm, T., Arnaud, L., & Parodis, I. (2024). Efficacy of lifestyle interventions in the management of systemic lupus erythematosus: a systematic review of the literature. Rheumatology international, 44(5), 765–778. https://doi.org/10.1007/s00296-024-05548-x
Replies (0)
